◆英語タイトル:ImmusanT Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10638
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
ImmusanT Inc (ImmusanT) is a clinical stage biotechnology company that discovers, develops and delivers peptide-based immune therapies for the treatment of patients with autoimmune diseases. The company develops its therapeutic vaccines using its epitope-specific immuno-therapy (ESIT) platform. Its lead candidate, Nexvax2, which has completed Phase 1 clinical trial intended for the treatment of celiac disease. The company also develops pipeline products for the treatment of type 1 diabetes and other human leukocyte antigen-linked diseases. It has collaboration with investigators from various research institutions, including The Walter and Eliza Hall Institute of Medical Research and University of Oslo, among others. ImmusanT is headquartered in Cambridge, Massachusetts, the US.
ImmusanT Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImmusanT Inc, Medical Devices Deals, 2012 to YTD 2018 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ImmusanT Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ImmusanT Raises Funds through Venture Financing 11
ImmusanT Raises USD40 Million in Series C Financing 12
ImmusanT Raises USD12 Million Series B Venture Financing 13
ImmusanT Inc – Key Competitors 14
ImmusanT Inc – Key Employees 15
ImmusanT Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Apr 04, 2018: ImmusanT Adds Robert J. Perez to Board of Directors 17
Product News 18
05/08/2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach 18
Clinical Trials 19
May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients 19
Feb 22, 2017: ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
ImmusanT Inc, Pharmaceuticals & Healthcare, Key Facts 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmusanT Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmusanT Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ImmusanT Inc, Medical Devices Deals, 2012 to YTD 2018 9
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ImmusanT Raises Funds through Venture Financing 11
ImmusanT Raises USD40 Million in Series C Financing 12
ImmusanT Raises USD12 Million Series B Venture Financing 13
ImmusanT Inc, Key Competitors 14
ImmusanT Inc, Key Employees 15
List of Figures
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmusanT Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImmusanT Inc, Medical Devices Deals, 2012 to YTD 2018 9